Pharmacist initiation of postexposure doxycycline for Lyme disease prophylaxis



      To enhance public access to prophylaxis for Lyme disease following an identifiedIxodes scapularis tick bite through pharmacist-initiated antibiotic therapy and to assess patient satisfaction with the pharmacy-based service provided.


      Independent community pharmacy in Charlestown, RI, from May to October 2012.

      Practice description

      Under a collaborative practice agreement, trained pharmacists at an independent pharmacy identified patients eligible for postexposure antibiotic prophylaxis following attachment and removal of anI. scapularis tick (commonly known as a deer tick) and dispensed two 100 mg tablets of doxycycline. Patients were included if they were 18 years or older, provided informed consent, had an estimated time of tick attachment of 36 hours or more, had the tick removed within 72 hours of visit, denied contraindications to doxycycline therapy, and reported telephone access for follow-up. Patients enrolled in the study protocol were given counseling related to doxycycline, signs and symptoms of Lyme disease, and future tick prevention strategies.

      Practice innovation

      Pharmacist initiation of doxycycline prophylaxis has not been described in the literature previously. Successful pharmacist initiation of antibiotic prophylaxis may have broader implications for states with endemic Lyme disease or other infectious disease public health concerns.

      Main outcome measures

      Patient self-reported adverse outcomes and satisfaction with the pharmacy-based service.


      Eight patients enrolled in the study and completed the follow-up survey. The results indicated a high level of satisfaction with the pharmacy services provided, with no reports of the subsequent development of Lyme disease symptoms or major adverse events.


      The project has expanded to three community pharmacy sites in southern Rhode Island based on this experience. Similar pharmacy-based collaborative practice models should be considered in highly endemic Lyme disease areas.


      To read this article in full you will need to make a payment
      APhA Member Login
      APhA Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Centers for Disease Control and Prevention. Lyme disease transmission. Accessed May 11, 2013.

        • Bacon R.M.
        • Kugeler K.J.
        • Mead P.S.
        • et al.
        Surveillance for Lyme disease: United States, 1992–2006.
        MMWR Surveill Summ. 2008; 57: 1-9
      2. Centers for Disease Control and Prevention. Lyme disease data. Accessed May 11, 2013.

        • Larkin J.
        • Mitty J.
        Introduction: Lyme disease.
        Medicine Health Rhode Island. 2008; 91: 208-209
        • Stricker R.B.
        • Johnson L.
        Lyme disease: the next decade.
        Infect Drug Resist. 2011; 4: 1-9
      3. Centers for Disease Control and Prevention. Post-treatment Lyme disease syndrome. Accessed May 11, 2013.

        • Nadelman R.B.
        • Nowakowski J.
        • Fish D.
        • et al.
        Prophylaxis with single dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite.
        N Engl J Med. 2001; 345: 79-84
        • Warshafsky S.
        • Lee D.H.
        • Francois L.K.
        • et al.
        Efficacy of antibiotic prophylaxis for the prevention of Lyme disease: an updated systematic review and meta-analysis.
        J Antimicrob Chemo. 2010; 65: 1137-1144
        • Wormser G.P.
        • Dattwyler R.J.
        • Shapiro E.D.
        • et al.
        The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America.
        Clin Infect Dis. 2006; 43: 1089-1134
      4. University of Rhode Island Tick Encounter Resource Center. Frequently asked questions: tickborne disease. Accessed July 31, 2013.

      5. Centers for Disease Control and Prevention. Lyme disease: a public information guide. Accessed May 11, 2013.

      6. Centers for Disease Control and Prevention. Ticks and Lyme disease. Accessed May 11, 2013.

        • Bearden D.T.
        • Holt T.
        Statewide impact of pharmacist-delivered adult influenza vaccinations.
        Am J Prev Med. 2005; 29: 450-452
        • Steyer T.E.
        • Ragucci K.R.
        • Pearson W.S.
        • Mainous 3rd, A.G.
        The role of pharmacists in the delivery of influenza vaccinations.
        Vaccine. 2004; 22: 1001-1006
        • Raine T.R.
        • Harper C.C.
        • Rocca C.H.
        • et al.
        Direct access to emergency contraception through pharmacies and effect on unintended pregnancy and STIs: a randomized controlled trial.
        JAMA. 2005; 293: 54-62
        • Dent L.A.
        • Harris K.J.
        • Noonan C.W.
        Randomized trial assessing the effectiveness of a pharmacist-delivered program for smoking cessation.
        Ann Pharmacother. 2009; 43: 194-201
        • Potter M.B.
        • Gildengorin G.
        • Wang Y.
        • et al.
        Comparative effectiveness of two pharmacy-based colorectal cancer screening interventions during an annual influenza vaccination campaign.
        J Am Pharm Assoc. 2010; 50: 181-187
        • Clark P.M.
        • Karagoz T.
        • Apikoglu-Rabus S.
        • Izzettin F.V.
        Effect of pharmacist-led patient education on adherence to tuberculosis treatment.
        Am J Health Syst Pharm. 2007; 64: 497-505
        • Taitel M.
        • Cohen E.
        • Duncan I.
        • Pegus C.
        Pharmacists as providers: targeting pneumococcal vaccinations to high risk populations.
        Vaccine. 2011; 29: 8073-8076
        • Gardner J.S.
        • Hutchings J.
        • Fuller T.S.
        • Downing D.
        Increasing access to emergency contraception through community pharmacies: lessons from Washington State.
        Fam Plann Perspect. 2001; 33: 172-175
        • Roberst S.
        • Gainsburgh R.
        Medication therapy management and collaborative drug therapy management.
        J Manag Care Pharm. 2010; 16: 67-68
        • Gardner J.S.
        • Miller L.
        • Downing D.F.
        • et al.
        Pharmacist prescribing of hormonal contraceptives: results of the Direct Access study.
        J Am Pharm Assoc. 2008; 48: 212-221
      7. Northwest Center for Public Health Practice. Collaborative drug therapy agreement for influenza antivirals in Washington State. Accessed May 11, 2013.

      8. Redlich GS. R.I.’s Good Samaritan Law offers protection: up to a point. Accessed May 24, 2013.

      9. SteelFisher G, Koonin LM, Rothholz MC, Patel A. New approaches during a pandemic for antiviral medication dispensing: collaboration that utilizes the community pharmacist [webinar]. Accessed May 24, 2013.